" class="no-js "lang="en-US"> Todor Jeliaskov - Medtech Alert
Friday, February 27, 2026

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Todor Jeliaskov

Todor Jeliaskov

About Todor Jeliaskov

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation of ultrasound imaging technology for cardiac interventions – 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound, the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.